Tests tumor-profile-guided treatment advice for ovarian cancer patients
Compares tumor-profile-based treatment advice with standard chemotherapy in adults with ovarian cancer.
Plain-language title generated from the registry record
Registry title: OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Key facts
- Where
- Aarau, Baden, Basel, Bern, Frauenfeld, Fribourg, Lucerne, Sankt Gallen, Winterthur, and Zurich, SwitzerlandSee the 10 sites
Where in Switzerland
- Kantonsspital Aarau AGAarau, SwitzerlandNot yet recruiting
- Kantonsspital Baden AGBaden, SwitzerlandTaking people
- Universitätsspital BaselBasel, SwitzerlandTaking people
- Inselspital Bern (University Hospital for Medical Oncology)Bern, SwitzerlandTaking people
- Thurgau AG Frauenfeld / MünsterlingenFrauenfeld, SwitzerlandTaking people
- HFR Fribourg - Hôpital cantonalFribourg, SwitzerlandTaking people
- Hirslanden Klinik St. AnnaLucerne, SwitzerlandTaking people
- HOCH Health Ostschweiz - Kantonsspital St. GallenSankt Gallen, SwitzerlandTaking people
- Kantonsspital WinterthurWinterthur, SwitzerlandTaking people
- University Hospital ZurichZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Swiss GO Trial Group
- Trial code
- NCT06466382
- Record updated
- 27 October 2026
- Original description
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.Read full original descriptionShow less
OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
Inclusion: Age ≥ 18 years; Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV; No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis; Envisaged surgical candidate for interval debulking after 2 cycles of treatment; Patients have adequate hematology, liver and kidney functions; Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures; ECOG 0-2; Written informed consent according to national legal and regulatory requirements prior to any project specific procedures.
Exclusion: Concurrent participation in another clinical trial on the same indication; Any other malignancy within the last 5 years which has an impact on the prognosis of the patient; Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance; ECOG ≥3; Pregnant or lactating women.